Current Perspectives on Analytical Method Validation of Empagliflozin: A Comprehensive Review
Abstract
Empagliflozin is an oral hypoglycemic drug belonging to the class of SGLT2 inhibitors. It acts on transporters in the proximal tubules of the kidneys to reduce blood glucose by promoting glucose excretion in the urine. This review examines various analytical method development strategies for Empagliflozin, with a focus on Quality by Design (QbD) approaches.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.